Various monoclonal antibodies (mAbs) and anticalines targeting c‐Met or its ligand (HGF), for example, DN30, rilotumumab, onartuzumab, and PRS‐100, have been recently tested in both preclinical and clinical trials, with encouraging results for the management of cancer.54, 55, 56. The gene discussed is MET; the disease is cancer.